Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
Source: SeekingAlpha
2026-06-29 11:19:58 ET
It has been more than a year since I last wrote about Acadia Pharmaceuticals ( ACAD ). Since then, we saw the failure of ACP-101 in Prader-Willi syndrome, which I wrote was a realistic possibility last year due to the issues I saw with prior clinical data. I also wrote at the time that Acadia looks well-positioned for value creation even if ACP-101 fails, and considering the lack of major upside surprises and the mentioned failure, I would call a share price trading 13% higher since my May 2025 update a small win....
Read the full article on Seeking Alpha
For further details see:
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
ACADIA Pharmaceuticals Inc.
NASDAQ: ACAD
ACAD Trading
-1.56% G/L:
$25.18 Last:
1,074,221 Volume:
$26.07 Open:
ACAD Latest News
$3,864,112,700
124,348,635
0.05%
128
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
